Brief: Asit Biotech Scientific Advisory Boards Provide Positive Recommendations On Development Of Gp-Asit+™

European Medical Solutions SA

29/03/2019 06:11

March 29 (Reuters) - ASIT BIOTECH SA  ASIT.BR :
    * ASIT BIOTECH’S SCIENTIFIC ADVISORY BOARDS (SAB) PROVIDE
POSITIVE
RECOMMENDATIONS ON THE CLINICAL DEVELOPMENT OF GP-ASIT+™
    * SAB CONFIRMED INTEREST OF A FOLLOW-UP STUDY TO ENHANCE
FUTURE
MARKET POSITIONING AND DIFFERENTIATION OF COMPOUND
    * SAB ACKNOWLEDGES BENEFIT OF GP-ASIT+™ AS A FAST ACTING
SHORT-COURSE TREATMENT COMPARED TO CURRENTLY AVAILABLE
IMMUNOTHERAPY PRODUCTS
    * RESULTS OF GPASIT011 STUDY AIMING TO CONFIRM FAVOURABLE
BENEFIT-RISK RATIO OF GP-ASIT+™ ARE EXPECTED BY END OF THIS YEAR

Source text for Eikon:  urn:newsml:reuters.com:*:nBw8n1Z9ta
Further company coverage:  ASIT.BR 

 (Gdynia Newsroom)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;))